COEP
Price:
$0.142
Market Cap:
$5.84M
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Heal...[Read more]
Industry
Biotechnology
IPO Date
2020-12-17
Stock Exchange
PNK
Ticker
COEP
According to Coeptis Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -225.59%. This represents a change of 281.52% compared to the average of -59.13% of the last 4 quarters.
The mean historical ROE of Coeptis Therapeutics, Inc. over the last ten years is -347.22%. The current -225.59% ROE has changed -35.03% with respect to the historical average. Over the past ten years (40 quarters), COEP's ROE was at its highest in in the November 2020 quarter at 1.08%. The ROE was at its lowest in in the March 2022 quarter at -145840555.87%.
Average
-347.22%
Median
-253.60%
Minimum
-1002.84%
Maximum
136.28%
Discovering the peaks and valleys of Coeptis Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 39.01%
Maximum Annual ROE = 136.28%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -1002.84%
Year | ROE | Change |
---|---|---|
2023 | -492.97% | -42.20% |
2022 | -852.90% | 39.01% |
2021 | -613.55% | -550.19% |
2020 | 136.28% | -1057.29% |
2019 | -14.24% | -Infinity% |
2018 | 0% | -100.00% |
2005 | 62.41% | -106.22% |
The current ROE of Coeptis Therapeutics, Inc. (COEP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-653.14%
5-year avg
-367.47%
10-year avg
-347.22%
Coeptis Therapeutics, Inc.’s ROE is less than SeaStar Medical Holding Corporation (443.82%), greater than Virios Therapeutics, Inc. (-130.35%), greater than ZyVersa Therapeutics, Inc. (-25512.50%), greater than Sonnet BioTherapeutics Holdings, Inc. (-383.41%), greater than Revelation Biosciences, Inc. (-311.33%), greater than Clearmind Medicine Inc. (-211.21%), greater than Hillstream BioPharma, Inc. (-172.28%), greater than Magenta Therapeutics, Inc. (-14.27%), greater than Quoin Pharmaceuticals, Ltd. (-126.19%), greater than Genelux Corporation (-105.05%), less than Comera Life Sciences Holdings, Inc. (67.46%), greater than Dyadic International, Inc. (-149.17%), greater than Cingulate Inc. (-113174.53%), greater than Monopar Therapeutics Inc. (-21731.73%), greater than YS Biopharma Co., Ltd. (-77.30%), greater than Allarity Therapeutics, Inc. (-328.22%), less than Kiromic BioPharma, Inc. (327.18%), greater than Aditxt, Inc. (-431.38%), greater than Palisade Bio, Inc. (-148.31%), less than Plus Therapeutics, Inc. (271.49%),
Company | ROE | Market cap |
---|---|---|
443.82% | $9.06M | |
-130.35% | $206.50K | |
-25512.50% | $2.70M | |
-383.41% | $4.27M | |
-311.33% | $2.51M | |
-211.21% | $7.54M | |
-172.28% | $4.17M | |
-14.27% | $42.44M | |
-126.19% | $2.45M | |
-105.05% | $82.55M | |
67.46% | $6.15K | |
-149.17% | $51.49M | |
-113174.53% | $15.61M | |
-21731.73% | $116.38M | |
-77.30% | $192.09M | |
-328.22% | $4.50M | |
327.18% | $1.47M | |
-431.38% | $2.62M | |
-148.31% | $4.73M | |
271.49% | $6.37M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Coeptis Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Coeptis Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Coeptis Therapeutics, Inc.'s ROE?
How is the ROE calculated for Coeptis Therapeutics, Inc. (COEP)?
What is the highest ROE for Coeptis Therapeutics, Inc. (COEP)?
What is the 3-year average ROE for Coeptis Therapeutics, Inc. (COEP)?
What is the 5-year average ROE for Coeptis Therapeutics, Inc. (COEP)?
How does the current ROE for Coeptis Therapeutics, Inc. (COEP) compare to its historical average?